Cited by 1,509Chemotherapy-induced cardiotoxicity and mitigationBioactive Compounds and Antitumor AgentsCancer therapeutics and mechanisms

The DOI matches its Crossref record.

Doxorubicin: The Good, the Bad and the Ugly Effect

Carvalho, Cristina, Santos, Renato, Cardoso, Susana, Correia, Sonia, Oliveira, Paulo, Santos, Maria, Moreira, Paula·2009·Current Medicinal Chemistry

DOI 10.2174/092986709788803312

Open this paper in CoChat — free account

Abstract

The anthracycline doxorubicin (DOX) is widely used in chemotherapy due to its efficacy in fighting a wide range of cancers such as carcinomas, sarcomas and hematological cancers. Despite extensive clinical utilization, the mechanisms of action of DOX remain under intense debate. A growing body of evidence supports the view that this drug can be a double-edge sword. Indeed, injury to nontargeted tissues often complicates cancer treatment by limiting therapeutic dosages of DOX and diminishing the quality of patients' life during and after DOX treatment. The literature shows that the heart is a preferential target of DOX toxicity. However, this anticancer drug also affects other organs like the brain, kidney and liver. This review is mainly devoted to discuss the mechanisms underlying not only DOX beneficial effects but also its toxic outcomes. Additionally, clinical studies focusing the therapeutic efficacy and side effects of DOX treatment will be discussed. Finally, some potential strategies to attenuate DOX-induced toxicity will be debated.

Integrity signals

Registry

Crossref · 10.2174/092986709788803312

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 601–700 of 1,000

Effective phthalocyanines mediated photodynamic therapy with doxorubicin or methotrexate combination therapy at sub-micromolar concentrations in vitro
Ali, S., Muhammad, S., Khurshid, A., Ikram, M., Maqsood, M., Fisher, C., Cathcart, J., & Lilge, L. D. (2018) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2018.02.010 · Cited by 20
An Updated Review on the Nanocarriers Based Co‐Delivery System of Chemo Drug Doxorubicin and Phytocompounds
Pandey, P., Verma, M., Lakhanpal, S., et al. (2024) · Polymers for Advanced Technologies · doi:10.1002/pat.70050 · Cited by 19
Nitrogen-doped carbon quantum dots as fluorescent sensor for doxorubicin and chlortetracycline: experimental and DFT insights
Lotfy, S., Aboelnga, M. M., Moawed, E. A., et al. (2026) · Nanoscale Advances · doi:10.1039/d6na00019c · Cited by 19
Doxorubicin Improves Cancer Cell Targeting by Filamentous Phage Gene Delivery Vectors
Tsafa, E., Bentayebi, K., Topanurak, S., Yata, T., Przystal, J., Fongmoon, D., Hajji, N., Waramit, S., Suwan, K., & Hajitou, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217867 · Cited by 19
“The cytostatic drug doxorubicin, one of the most effective neoplastic drugs, is a well-known chemotherapeutic agent used in the treatment of a wide variety of cancers for over 30 years, mainly in combination with other drugs against solid tumors [28,29].”
Background
Anti‐Interleukin‐16‐Neutralizing Antibody Attenuates Cardiac Inflammation and Protects against Cardiac Injury in Doxorubicin‐Treated Mice
Zhang, J., Yang, Z., Liang, Z., et al. (2021) · Mediators of Inflammation · doi:10.1155/2021/6611085 · Cited by 19
“As a drug that has been widely used in clinical chemotherapy, doxorubicin (DOX) has slowly been withdrawn as a frontline treatment due to severe cardiotoxicity and cardiac injury and further grave clinical consequences [1, 2].”
Carbosilane Glycodendrimers for Anticancer Drug Delivery: Synthetic Route, Characterization, and Biological Effect of Glycodendrimer–Doxorubicin Complexes
Müllerová, M., Maciel, D., Nunes, N., et al. (2021) · Biomacromolecules · doi:10.1021/acs.biomac.1c01264 · Cited by 19
Delivery of anti-cancer drugs using microbubble-assisted ultrasound in digestive oncology: from preclinical to clinical studies
Escoffre, J., Sekkat, N., Oujagir, E., et al. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2061459 · Cited by 19
“(DOX) is one of the most powerful anti-cancer drugs prescribed on its own or in combination with other drugs for the treatment of solid tumors [21].”
Background
Ranolazine alleviated cardiac/brain dysfunction in doxorubicin-treated rats
Chunchai, T., Arinno, A., Ongnok, B., Pantiya, P., Khuanjing, T., Prathumsap, N., Maneechote, C., Chattipakorn, N., & Chattipakorn, S. C. (2022) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2022.104818 · Cited by 19
Sphingosylphosphorylcholine ameliorates doxorubicin-induced cardiotoxicity in zebrafish and H9c2 cells by reducing excessive mitophagy and mitochondrial dysfunction
Zhou, J., Lu, Y., Li, Z., Wang, Z., Kong, W., & Zhao, J. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.116207 · Cited by 19
A photocatalytic carbon monoxide-generating effervescent microneedle patch for improved transdermal chemotherapy
Fu, J., Yu, W., Qian, X., et al. (2023) · Journal of Materials Chemistry B · doi:10.1039/d2tb02613a · Cited by 19
Tumor targeted cancer membrane-camouflaged ultra-small Fe nanoparticles for enhanced collaborative apoptosis and ferroptosis in glioma
Wang, J., Yang, J., Liu, K., Yuan, J., Shi, Y., Li, H., & Zhao, L. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100780 · Cited by 20
Anthraquinone as emerging contaminant: technological, toxicological, regulatory and analytical aspects
Valduga, A. T., Gonçalves, I. L., Puton, B. M. S., Hennig, B. D. L., & de Brito, E. S. (2023) · Toxicological Research · doi:10.1007/s43188-023-00202-3 · Cited by 21
Allicin Overcomes Doxorubicin Resistance of Breast Cancer Cells by Targeting the Nrf2 Pathway
Shi, G., Li, X., Wang, W., Hou, L., Yin, L., & Wang, L. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01215-x · Cited by 21
“Dox-orubicin is mainly used for hematological system tumors and some solid tumors, such as acute leukemia, lymphoma, BC, lung cancer, gastric cancer, ovarian cancer, soft tissue sarcoma, and so on [6, 7].”
Tetrastigma hemsleyanum polysaccharide combined with doxorubicin promote ferroptosis and immune function in triple-negative breast cancer
Shang, Y., Zhao, M., Chen, S., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.133424 · Cited by 19
Doxorubicin combined with celecoxib inhibits tumor growth of medullary thyroid carcinoma in xenografted mice
Meng, X., Zhang, Q., Zheng, G., Pang, R., Hua, T., Yang, S., & Li, J. (2014) · Oncology Letters · doi:10.3892/ol.2014.2050 · Cited by 19
“DOX toxicity in cancer cells primarily occurs due to its ability to intercalate between the DNA strands to act as a topoisomerase II inhibitor and/or bind covalently to proteins involved in DNA replication and transcription (7).”
BackgroundInfluential
Ocotillol Enhanced the Antitumor Activity of Doxorubicin via p53-Dependent Apoptosis
Wang, H., Yu, P., Bai, J., Zhang, J., Kong, L., Zhang, F., Du, G., Pei, S., Zhang, L., Jiang, Y., et al. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/468537 · Cited by 19
Cellular Robustness Conferred by Genetic Crosstalk Underlies Resistance against Chemotherapeutic Drug Doxorubicin in Fission Yeast
Tay, Z., Eng, R. J., Sajiki, K., Lim, K. K., Tang, M. Y., Yanagida, M., & Chen, E. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055041 · Cited by 19
“A major challenge in the usage of DOXO lies in the control of the administration dose as increase dosage heightens the propensity of adverse drug-linked cytotoxic effect, especially cardiotoxicity [1,2].”
Background
Boswellic acids ameliorate doxorubicin-induced nephrotoxicity in mice: a focus on antioxidant and antiapoptotic effects
Sami, M. M., Ali, E., Galhom, R. A., et al. (2019) · Egyptian Journal of Basic and Applied Sciences · doi:10.1080/2314808x.2019.1586359 · Cited by 19
Application and biomolecular study of functionalized folic acid-dendrimer nanoparticles in drug delivery
Chanphai, P., Thomas, T., & Tajmir‐Riahi, H. A. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1717994 · Cited by 19
“Doxorubicin is a major antitumor drug used in chemotherapy due to its efficacy in fighting a wide range of cancers (Agudelo, Bourassa, B erub e, & Tajmir-Riahi, 2014; Carvalho et al., 2009; Ma & Mumper, 2013).”
Background
Combination Therapy with Doxorubicin-Loaded Reduced Albumin Nanoparticles and Focused Ultrasound in Mouse Breast Cancer Xenografts
Kim, D., Lee, S. S., Yoo, W. Y., Moon, H., Cho, A., Park, S. Y., Kim, Y.-S., Kim, H. R., & Lee, H. J. (2020) · Pharmaceuticals · doi:10.3390/ph13090235 · Cited by 21
RETRACTED: Nanoformulated Ajwa (Phoenix Dactylifera) Bioactive Compounds Improve the Safety of Doxorubicin without Compromising Its Anticancer Efficacy in Breast Cancer
Godugu, K., El‐Far, A. H., Jaouni, S. K. A., et al. (2020) · Molecules · doi:10.3390/molecules25112597 · Cited by 19
“One of the most interesting ways to treat metastatic breast cancer is through DOX-based regimens [9,10].”
Background
Retracted
In-vitro Evaluation of Isatin Derivatives as Potent Anti-Breast Cancer Agents against MCF-7, MDA MB 231, MDA-MB 435 and MDA-MB 468 Breast Cancers Cell Lines: A Review
Chauhan, G., Pathak, D. P., Ali, F., Dubey, P., & Khasimbi, S. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210903130152 · Cited by 18
Inhibition of Glutamine Cellular Uptake Contributes to the Cytotoxic Effect of Xanthohumol in Triple-Negative Breast Cancer Cells
Carmo, F., Silva, C., & Martel, F. (2022) · Nutrition and Cancer · doi:10.1080/01635581.2022.2076889 · Cited by 18
Development and DoE-ANN based optimization of novel swellable matrix-diffusible doxorubicin loaded zinc oxide nanoflowers using sonochemical-precipitation method
Ijaz, S., Sultana, M., Shamim, R., et al. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122584 · Cited by 18
Shikonin alleviates doxorubicin-induced cardiotoxicity via Mst1/Nrf2 pathway in mice
Tuo, H., Li, W., Zhao, W., Zhao, J., Li, D., & Lin, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-51675-7 · Cited by 20
Intercalation of quantum dots as the new signal acquisition and amplification platform for sensitive electrochemiluminescent detection of microRNA
Chen, Y., Xiang, Y., Yuan, R., et al. (2015) · Analytica Chimica Acta · doi:10.1016/j.aca.2015.07.059 · Cited by 18
Effect of selected catechins on doxorubicin antiproliferative efficacy and hepatotoxicity in vitro
Rudolfová, P., Hanušová, V., Skálová, L., Bártíková, H., Matoušková, P., & Boušová, I. (2014) · Acta Pharmaceutica · doi:10.2478/acph-2014-0018 · Cited by 18
First Evidence of the Liposome-Mediated Deintercalation of Anticancer Drug Doxorubicin from the Drug–DNA Complex: A Spectroscopic Approach
Das, A., Adhikari, C., Nayak, D., et al. (2015) · Langmuir · doi:10.1021/acs.langmuir.5b03702 · Cited by 18
Effects of Adrenomedullin on Doxorubicin-Induced Cardiac Damage in Mice
Yoshizawa, T., Takizawa, S., Shimada, S., et al. (2016) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b15-00832 · Cited by 18
Taming the Wildness of “Trojan-Horse” Peptides by Charge-Guided Masking and Protease-Triggered Demasking for the Controlled Delivery of Antitumor Agents
Shi, N., & Qi, X. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b01056 · Cited by 18
AKAP-Lbc mediates protection against doxorubicin-induced cardiomyocyte toxicity
Caso, S., Maric, D., Arambasic, M., Cotecchia, S., & Diviani, D. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.09.007 · Cited by 18
Efficacy of metformin in mediating cellular uptake and inducing apoptosis activity of doxorubicin
Shafa, M. H., Jalal, R., Kosari, N., & Rahmani, F. (2018) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2018.09.023 · Cited by 17
Doxorubicin sensitizes cancer cells to Smac mimetic via synergistic activation of the CYLD/RIPK1/FADD/caspase-8-dependent apoptosis
Yang, C., Ran, Q., Zhou, Y., Liu, S., Zhao, C., Yu, X., Zhu, F., Ji, Y., Du, Q., Yang, T., et al. (2020) · APOPTOSIS · doi:10.1007/s10495-020-01604-6 · Cited by 18
Coumestrol ameliorates doxorubicin-induced cardiotoxicity via activating AMPKα
Wu, Z., Rao, M., Xu, S., et al. (2020) · Free Radical Research · doi:10.1080/10715762.2020.1822525 · Cited by 18
Ultrasound-Mediated Cavitation Enhances EGFR-Targeting PLGA-PEG Nano-Micelle Delivery for Triple-Negative Breast Cancer Treatment
Chen, L., Zhang, T., Sun, S., et al. (2021) · Cancers · doi:10.3390/cancers13143383 · Cited by 18
“Doxorubicin (DOX) is an anthracycline chemotherapeutic drug that is widely used to efficiently treat diverse tumor types, including breast cancer, lung cancer, and lymphoma [11].”
Background
pH-sensitive doxorubicin-tocopherol succinate prodrug encapsulated in docosahexaenoic acid-based nanostructured lipid carriers: An effective strategy to improve pharmacokinetics and reduce toxic effects
Lages, E. B., Fernandes, R. S., Andrade, M. M. S., Paiyabhroma, N., de Oliveira, R. B., Fernandes, C., Cassali, G. D., Sicard, P., Richard, S., de Barros, A. L. B., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112373 · Cited by 18
Combination of glycosphingosomes and liposomal doxorubicin shows increased activity against dimethyl-α-benzanthracene-induced fibrosarcoma in mice
Khan, M. A., Aljarbou, A. N., Aldebasi, Y. H., et al. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s86467 · Cited by 18
“Doxorubicin (Dox) has been in use for the treatment of a wide variety of solid and hematologic cancers.(17,18) However, the use of Dox shows considerable cardiotoxicity in cancer patients.”
Background
Reduction-responsive modification-induced higher efficiency for attenuation of tumor metastasis of low molecular weight heparin functionalized liposomes
Tian, J., Han, M., Wang, Y., Qian, K., Ke, X., & Ci, T. (2016) · RSC Advances · doi:10.1039/c5ra27227k · Cited by 18
Multifunctional PLGA nanoparticles combining transferrin-targetability and pH-stimuli sensitivity enhanced doxorubicin intracellular delivery and in vitro antineoplastic activity in MDR tumor cells
Scheeren, L. E., Nogueira-Librelotto, D. R., Mathes, D., Pillat, M. M., Macedo, L. B., Mitjans, M., Vinardell, M. P., & Rolim, C. M. B. (2021) · Toxicology in Vitro · doi:10.1016/j.tiv.2021.105192 · Cited by 17
Designing Functionalized Polyelectrolyte Microcapsules for Cancer Treatment
Kalenichenko, D., Nifontova, G., Karaulov, A. V., et al. (2021) · Nanomaterials · doi:10.3390/nano11113055 · Cited by 17
Interaction of doxorubicin delivered by superparamagnetic iron oxide nanoparticles with DNA
Dukhopelnikov, E. V., Blyzniuk, J. N., Skuratovska, A., Bereznyak, E. G., & Gladkovskaya, N. (2022) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2022.112815 · Cited by 17
Modeling neurotoxin-induced neuroinflammation with chemotherapy
Tolba, M. F., Sedky, N. K., Ali, M. A., & Abdollah, M. R. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89833-1.00049-5 · Cited by 17
RETRACTED ARTICLE: Modulatory effect of liraglutide on doxorubicin-induced testicular toxicity and behavioral abnormalities in rats: role of testicular-brain axis
Alafifi, S. A., Wahdan, S. A., Elhemiely, A. A., Elsherbiny, D. A., & Azab, S. S. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02504-7 · Cited by 17
“Doxorubicin (DOX) is a well-known anticancer drug approved by the FDA for the treatment of various types of malignancies including acute leukemia, malignant lymphomas, and solid tumors, especially small-cell carcinoma of the lung (Lorusso et al. 2007; Ludwig et al. 2007; Carvalho et al. 2009).”
Retracted
ESI-IM-MS characterization of cyclodextrin complexes and their chemically cross-linked alpha (α-), beta (β-) and gamma (γ-) cyclodextrin particles as promising drug delivery materials with improved bioavailability
Yilmaz, A. S., Öztürk, S., Salih, B., Ayyala, R. S., & Şahiner, N. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113522 · Cited by 20
Resveratrol may dose-dependently modulate nephrin and OTULIN levels in a doxorubicin-induced nephrotoxicity model
Yalçın, T., Kaya, S., & Kuloğlu, T. (2023) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2023.2268717 · Cited by 17
“The antitumor activity of DOX binds to proteins involved in DNA replication and transcription, causing cell death through inhibition of DNA, RNA and protein synthesis (Carvalho et al. 2009).”
Background
Porphyrin-based covalent organic frameworks as doxorubicin delivery system for chemo-photodynamic synergistic therapy of tumors
Chen, P., Li, Y., Dai, Y., et al. (2024) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2024.104063 · Cited by 17
Doxorubicin-induced neurotoxicity differently affects the hippocampal formation subregions in adult mice
Dias-Carvalho, A., Ferreira, M., Reis-Mendes, A., Ferreira, R. M., Bastos, M. D. L., Fernandes, E. G. R., Sá, S. I., Capela, J. P., Carvalho, F. D., & Costa, V. M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e31608 · Cited by 17
Effects of Doxorubicin and Fenofibrate on the Activities of NADH Oxidase and Citrate Synthase in Mice
Yao, C.-X., Li, W., Zhang, S., et al. (2011) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2011.00748.x · Cited by 17
Combination of Protoporphyrin IX-mediated Sonodynamic Treatment with Doxorubicin Synergistically Induced Apoptotic Cell Death of a Multidrug-Resistant Leukemia K562/DOX Cell Line
Wang, X., Jia, Y., Su, X., et al. (2015) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2015.06.001 · Cited by 17
“Doxorubicin hydrochloride (DOX), an anthracycline antineoplastic agent and cornerstone of many chemotherapeutic protocols, has been widely used in cancer treatment, including many kinds of malignancies (Carvalho et al. 2009).”
Background
Towards 99m Tc-based imaging agents with effective doxorubicin mimetics: a molecular and cellular study
Imstepf, S., Pierroz, V., Raposinho, P., et al. (2016) · Dalton Transactions · doi:10.1039/c6dt00871b · Cited by 17
An Indigenous Plant Bael (Aegle Marmelos (L.) Correa) Extract Protects Against the Doxorubicin-Induced Cardiotoxicity in Mice
Jagetia, G. C., & Ponemone, V. (2015) · Biochemistry & Physiology Open Access · doi:10.4172/2168-9652.1000163 · Cited by 17
“Regardless of the specific mechanism, DNA, RNA and protein synthesis are all inhibited, arresting cell proliferation in the G1, S-phase and G2, of the cell cycle [14,15].”
Background
Low-density lipoprotein peptide-combined DNA nanocomplex as an efficient anticancer drug delivery vehicle
Zhang, N., Tao, J., Hua, H., et al. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.04.022 · Cited by 17
Cytotoxicity of doxorubicin-conjugated poly[N-(2-hydroxypropyl)methacrylamide]-modified γ-Fe2O3 nanoparticles towards human tumor cells
Plichta, Z., Kozak, Y., Panchuk, R. R., et al. (2018) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.9.236 · Cited by 17
Melatonin protects against apoptosis of megakaryocytic cells via its receptors and the AKT/mitochondrial/caspase pathway
Yang, M., Li, L., Chen, S., et al. (2020) · Aging · doi:10.18632/aging.103483 · Cited by 17
“Doxorubicin is an anthracycline antibiotic widely used in cancer chemotherapy [19] and is known to induce cell cycle G2/M phase arrest and cell apoptosis in cancer cells and normal cells [20].”
Background
Polar Lipid Fraction E from Sulfolobus acidocaldarius and Dipalmitoylphosphatidylcholine Can Form Stable yet Thermo-Sensitive Tetraether/Diester Hybrid Archaeosomes with Controlled Release Capability
Ayesa, U., & Chong, P. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218388 · Cited by 17
Comparative Analysis of Cell–Cell Contact Abundance in Ovarian Carcinoma Cells Cultured in Two- and Three-Dimensional In Vitro Models
Kutova, O. M., Sencha, L. M., Pospelov, A. D., Dobrynina, O., Brilkina, A. A., Cherkasova, E. I., & Владимировна, Б. И. (2020) · Biology · doi:10.3390/biology9120446 · Cited by 17
Aldose reductase regulates doxorubicin-induced immune and inflammatory responses by activating mitochondrial biogenesis
Sonowal, H., Saxena, A., Qiu, S. M., Srivastava, S., & Ramana, K. V. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173884 · Cited by 18
Nanotheranostics through Mitochondria-targeted Delivery with Fluorescent Peptidomimetic Nanohybrids for Apoptosis Induction of Brain Cancer Cells
Carvalho, I. C., Mansur, A., Carvalho, S., & Mansur, H. (2021) · Nanotheranostics · doi:10.7150/ntno.54491 · Cited by 15
“heart), which restricts the correct dosage of the drug and reduce the quality of life of patients under clinical treatment with DOX [81].”
Evaluation of exosome derivatives as bio-informational reprogramming therapy for cancer
González, M. J., Kweh, M. F., Biava, P. M., Olalde, J., Toro, A. P., Goldschmidt‐Clermont, P. J., & White, I. A. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02768-8 · Cited by 19
“Doxorubicin is a chemotherapy drug approved by the FDA, which is commonly used due to its efficacy in fighting multiple types of cancer with acceptable response rates and overall survival [48].”
Background
Investigation of squalene-doxorubicin distribution and interactions within single cancer cell using Raman microspectroscopy
Rammal, H., Assaad, A. A., Dosio, F., et al. (2021) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2021.102404 · Cited by 17
Development of doxorubicin-loaded chitosan–heparin nanoparticles with selective anticancer efficacy against gastric cancer cells in vitro through regulation of intrinsic apoptosis pathway
Yang, H., Sun, A., Yang, J., et al. (2021) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2021.103266 · Cited by 17
Atomistic investigations of polymer-doxorubicin-CNT compatibility for targeted cancer treatment: A molecular dynamics study
Kamath, A., Laha, A., Pandiyan, S., et al. (2021) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2021.118005 · Cited by 17
Biological macromolecules in drug delivery
Nayak, A. K., Hasnain, M. S., Behera, A., Dhara, A. K., & Pal, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85759-8.00015-4 · Cited by 21
Aidi injection altered the activity of CYP2D4, CYP1A2, CYP2C19, CYP3A2, CYP2E1 and CYP2C11 in normal and diethylnitrosamine-induced hepatocellular carcinoma in rats
Lü, Y., Wang, Y., He, Y., et al. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114930 · Cited by 17
Long noncoding RNA NONMMUT015745 inhibits doxorubicin-mediated cardiomyocyte apoptosis by regulating Rab2A-p53 axis
Cai, H., Tian, P., Ju, J., Wang, T., Chen, X., Wang, K., Wang, F., Yu, X., Wang, S., Wang, Y., et al. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01144-9 · Cited by 17
“However, the clinical use of DOX is limited due to severe dose-dependent and cumulative cardiotoxicity [3].”
Background
Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis
Cardani, D., Sardi, C., Ferla, B. L., D’Orazio, G., Sommariva, M., Marcucci, F., Olivero, D., Tagliabue, E., Koepsell, H., Nicotra, F., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-23 · Cited by 17
“Severe mucositis is especially common among patients who receive aggressive myeloablative chemotherapy and in patients who receive therapy for head and neck cancer [1-3].”
Background
Calcium modulation of doxorubicin cytotoxicity in yeast and human cells
Nguyen, T. T. T., Lim, Y. J., Fan, M. H. M., Jackson, R. A., Lim, K. K., Ang, W. H., Ban, K. H.-K., & Chen, E. S. (2016) · Genes to Cells · doi:10.1111/gtc.12346 · Cited by 17
“Cancer is a major global health problem and, although chemotherapy remains the mainstay treatment for cancer management, treatment outcomes are far from desirable (Castells et al. 2012).”
Background
Exercise Training Prevents Doxorubicin-induced Mitochondrial Dysfunction of the Liver
Hinkley, J. M., Morton, A. B., Ichinoseki‐Sekine, N., Huertas, A. M., & Smuder, A. J. (2019) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000001887 · Cited by 17
“DOX-induced damage to the liver is irreversible in a dose-dependent manner, and it is estimated that 40% of patients undergoing DOX treatment will suffer from liver injury (2).”
Virus-inspired biogenic delivery system for advancing cancer therapy
Sun, D., Hao, L., Mu, Q., Chu, C., Liu, G., & Liu, C. (2025) · Biomedical Technology · doi:10.1016/j.bmt.2025.100069 · Cited by 17
Marine Natural Products in Inflammation‐Related Diseases: Opportunities and Challenges
Zhang, T., Ouyang, Z., Zhang, Y., Sun, H., Kong, L., Xu, Q., Qu, J., & Sun, Y. (2025) · Medicinal Research Reviews · doi:10.1002/med.22109 · Cited by 19
“The anthracycline doxorubicin (DOX) is extensively used in chemotherapy for its effectiveness against a diverse range of cancers, including carcinomas, sarcomas, and hematological malignancies [15, 16].”
Assessment of the Biological Effects of a Multifunctional Nano-Drug-Carrier and Its Encapsulated Drugs
Song, Y., Zhao, R., Hu, Y., Hao, F., Li, N., Nie, G., Tang, H., & Wang, Y. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00513 · Cited by 16
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia: a literature review of pharmaceutical and clinical aspects
Zhu, Y., Wang, F., Zhao, Y., et al. (2020) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2020-002311 · Cited by 16
Temporary blockade of interferon-γ ameliorates doxorubicin-induced cardiotoxicity without influencing the anti-tumor effect
Ma, P., Qin, Y., Cao, H., Erben, U., Chen, N., & Qin, Z. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110587 · Cited by 15
Targeted drug release system based on pH-responsive PAA-POSS nanoparticles
Kim, W. J., Lee, E. H., Kwon, Y., et al. (2022) · RSC Advances · doi:10.1039/d2ra01141g · Cited by 16
A Face-To-Face Comparison of Tumor Chicken Chorioallantoic Membrane (TCAM) In Ovo with Murine Models for Early Evaluation of Cancer Therapy and Early Drug Toxicity
Rupp, T., Legrand, C., Hunault, M., et al. (2022) · Cancers · doi:10.3390/cancers14143548 · Cited by 16
“Doxorubicin is used against a wide range of cancers such as carcinomas, sarcomas, and hematological cancers [37].”
Background
Traditional Medicinal Plants as a Source of Inspiration for Osteosarcoma Therapy
Kazantseva, L., Becerra, J., & Santos‐Ruiz, L. (2022) · Molecules · doi:10.3390/molecules27155008 · Cited by 18
Recent Clinical Successes in Liposomal Nanomedicines
Gu, W., Andrews, G. P., & Tian, Y. (2023) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.0201009 · Cited by 16
A proof-of-concept assay for quantitative and optical assessment of drug-induced toxicity in renal organoids
Dilz, J., Auge, I., Groeneveld, K., Reuter, S., & Mrowka, R. (2023) · Scientific Reports · doi:10.1038/s41598-023-33110-5 · Cited by 19
“Doxorubicin (DOX) is a chemotherapeutic agent used to treat various types of cancer 31,32 .”
Background
Mixed Copolymer Micelles for Nanomedicine
Gerardos, A. M., Balafouti, A., & Pispas, S. (2023) · Nanomanufacturing · doi:10.3390/nanomanufacturing3020015 · Cited by 16
“Apoptosis will eventually result from these i te ac s [45].”
Background
Taurine Protects Doxorubicin-Induced Hepatotoxicity via Its Membrane-Stabilizing Effect in Rats
Gedikli, E., Barış, V. Ö., Yersal, N., et al. (2023) · Life · doi:10.3390/life13102031 · Cited by 16
“Doxorubicin is a chemotherapeutic agent used in the treatment of solid tumors and hematologic cancers [6].”
Background
Protective effects of arbutin against doxorubicin-induced cardiac damage
Birdal, O., Okkay, I. F., Okkay, U., et al. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09488-4 · Cited by 16
Novel PLGA-based nanoformulation decreases doxorubicin-induced cardiotoxicity
Drinković, N., Beus, M., Barbir, R., Debeljak, Ž., Lovaković, B. T., Kalčec, N., Ćurlin, M., Bekavac, A., Gorup, D., Mamić, I., et al. (2024) · Nanoscale · doi:10.1039/d3nr06269d · Cited by 18
[Retracted] Silencing XIAP suppresses osteosarcoma cell growth, and enhances the sensitivity of osteosarcoma cells to doxorubicin and cisplatin
Qu, Y., Xia, P., Zhang, S., et al. (2021) · Oncology Reports · doi:10.3892/or.2021.8213 · Cited by 16
Retracted
Synthesis, Characterization, and Viscoelastic Behavior of Thermothickening Poly (N-Isopropylacrylamide-Methacrylicacide-Vinylpyrrolidone) Nanogels as an Injectable Biocompatible Drug Carrier
Mamaghani, P. Y., Kaffashi, B., Salehi, R., & Davaran, S. (2014) · International Journal of Polymeric Materials · doi:10.1080/00914037.2014.886236 · Cited by 16
Tumor Specific and Renal Excretable Star-like Triblock Polymer–Doxorubicin Conjugates for Safe and Efficient Anticancer Therapy
Tang, H., Zhang, J., Tang, J. T., Shen, Y., Guo, W., Zhou, M., Wang, R., Jiang, N., Gan, Z., & Yu, Q. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00425 · Cited by 16
A novel agent attenuates cardiotoxicity and improves antitumor activity of doxorubicin in breast cancer cells
Zhang, Y., Deng, H., Zhou, H., Lu, Y., Shan, L., Lee, S. M., & Cui, G. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27880 · Cited by 20
“The cardiotoxicity‐induced by Dox has greatly limited its clinical application.(6) The mechanisms underlying Dox‐induced cardiotoxicity are not fully characterized but are likely to”
Background
Nanoliposomal multi-drug delivery system with reduced toxicity and multi-drug resistance
Yang, J., Wen, C., Pan, C., Guo, H., Zhao, W., Zhang, J., Zhu, Y., Zhang, Y., & Zhang, L. (2019) · Journal of Materials Science · doi:10.1007/s10853-019-03573-x · Cited by 16
Highly biocompatible thermosensitive nanocomposite gel for combined therapy of hepatocellular carcinoma via the enhancement of mitochondria related apoptosis
Fu, H., Huang, L., Xu, C., Zhang, J., Li, D., Ding, L., Liu, L., Dong, Y. W., Wang, W., & Duan, Y. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2019.102062 · Cited by 16
Synergistic anticancer activity by co-delivered nanosized dual therapeutic agents and siRNA in colon cancer
Ray, L. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.101351 · Cited by 16
Doxorubicin and α-Mangostin oppositely affect luminal breast cancer cell stemness evaluated by a new retinaldehyde-dependent ALDH assay in MCF-7 tumor spheroids
Bissoli, I., & Muscari, C. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109927 · Cited by 16
Dissecting Chemical Composition and Cardioprotective Effects of Fuzhengkangfu Decoction against Doxorubicin-Induced Cardiotoxicity by LC–MS and Bioinformatics Approaches
Zhong, Y., Li, M., Zhang, X., Chen, L., Wáng, Y., & Xu, Y. (2020) · ACS Omega · doi:10.1021/acsomega.0c01494 · Cited by 14
Satureja khuzistanica Jamzad essential oil prevents doxorubicin-induced apoptosis via extrinsic and intrinsic mitochondrial pathways
Dezfoulian, O., Seyedan, A., & Alirezaei, M. (2020) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.297851 · Cited by 16
“Although the positive effects of this chemotherapeutic drug are well determined on neoplastic cells, exclusively by activation of the apoptotic pathway, however, toxic effects of doxorubicin are still a major concern (2,3).”
Background
Impact of ellagic acid application on doxorubicin-induced cardiovascular toxicity model
Šalinger-Martinović, S., Ćosić, V., Stojiljković, N. I., et al. (2021) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2020-0404 · Cited by 16
Combination therapy with miR-34a and doxorubicin synergistically induced apoptosis in T-cell acute lymphoblastic leukemia cell line
Najjary, S., Mohammadzadeh, R., Mansoori, B., et al. (2021) · Medical Oncology · doi:10.1007/s12032-021-01578-8 · Cited by 16
“Doxorubicin is one of the strongest FDA chemotherapy drugs that offer great therapeutic potential and is an effective treatment for acute lymphoblastic leukemia (ALL) [12].”
Background
Engineered microneedle systems for topical cancer therapy
Jiang, X., Xia, W., Pan, J., Yang, W., Zhang, S., Li, C., Zan, T., Lai, Y., Xu, Z., & Yu, H. (2023) · Applied Materials Today · doi:10.1016/j.apmt.2023.101774 · Cited by 16
The effectiveness of oracin in enhancing the cytotoxicity of doxorubicin through the inhibition of doxorubicin deactivation in breast cancer MCF7 cells
Hanušová, V., Králová, V., Schröterová, L., et al. (2010) · Xenobiotica · doi:10.3109/00498254.2010.508821 · Cited by 16
“Cancer cell mortality has been correlated with both dose and exposure time, but DOX systemic toxicity, especially cardiotoxicity, strongly limits the maximal therapeutic dose of DOX (Carvalho et al., 2009).”
Background
Effect of Chemical Binding of Doxorubicin Hydrochloride to Gold Nanoparticles, Versus Electrostatic Adsorption, on the In Vitro Drug Release and Cytotoxicity to Breast Cancer Cells
Zayed, G., Kamal, I., Abdelhafez, W. A., et al. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2393-6 · Cited by 16
A precision medicine approach to defining the impact of doxorubicin on the bioenergetic-metabolite interactome in human platelets
Smith, M. R., Chacko, B. K., Johnson, M. S., et al. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101311 · Cited by 16
Fucoxanthin attenuates doxorubicin-induced cardiotoxicity via anti-oxidant and anti-apoptotic mechanisms associated with p38, JNK and p53 pathways
Zhao, Y.-Q., Zhang, L., Zhao, G., Chen, Y., Sun, K., & Wang, B. (2019) · Journal of Functional Foods · doi:10.1016/j.jff.2019.103542 · Cited by 16
Isoliquiritigenin as a modulator of the Nrf2 signaling pathway: potential therapeutic implications
Qiu, M., Ma, K., Zhang, J., Zhao, Z., Wang, S., Wang, Q., & Xu, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1395735 · Cited by 18
“Given that the liver serves as a crucial metabolic organ in the human body, it has been observed that during doxorubicin therapy, the liver is exposed to high concentrations of the drug and experiences the most pronounced impact (Carvalho et al., 2009).”
Background

Authors: Carvalho, C., Santos, R., Cardoso, S., Correia, S., Oliveira, P., Santos, M., & Moreira, P.
Affiliations: Centro de Neurociências e Biologia Celular (PT)
Corresponding author: Moreira, Paula
ORCID: Carvalho, Cristina
Santos, Renato
Cardoso, Susana
Oliveira, Paulo
Santos, Maria
Moreira, Paula
Venue: Current Medicinal Chemistry
Publisher: Bentham Science Publishers Ltd.
Published: 2009-09-01
Volume: 16
Issue: 25
Pages: 3267-3285
ISSN: 0929-8673 (ISSN-L)
DOI: 10.2174/092986709788803312
OpenAlex: W2102897174
Cited by: 1,509
References: 0
Citations by year: 2026: 102 · 2025: 147 · 2024: 174 · 2023: 169 · 2022: 153 · 2021: 150 · 2020: 120 · 2019: 85 · 2018: 84 · 2017: 53 · 2016: 63 · 2015: 62 · 2014: 43 · 2013: 35 · 2012: 29
FWCI: 14.12
Type: journal article
Language: en
Open access: closed
Locations: Current Medicinal Chemistry (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Keywords: doxorubicin, anthracyclines, cardiotoxicity, drug toxicity mechanisms, anticancer mechanism, neurotoxicity, nephrotoxicity, hepatotoxicity, chemotherapy side effects
MeSH terms: Antibiotics, Antineoplastic, Doxorubicin, Humans, Molecular Conformation, Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Doxorubicin: The Good, the Bad and the Ugly Effect

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks